Empagliflozin and metformin 12.5/1000 mg

Empagliflozin and metformin 5/1000 mg

Empaxa-met is combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin, a biguanide, indicated for the treatment of type 2 diabetes mellitus (T2D).

• Highly effective treatment for T2D at any disease stage.
• Has additive effect in reducing HbA1c, post-prandial and fasting blood glucose levels.
• Has cardioprotective and renoprotective benefits.
• Low risk of hypoglycemia.
• Exerts a favorable effect on nonglycemic outcomes, including blood pressure.
• Promotes weight loss.
• Well-tolerated